Head-to-head evidence
LY03003 vs LY03009
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
LY03003
Developed by Luye Pharma Group
NCT04571164 · Phase 3 · completed
The trial randomized 294 participants to LY03003 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical UPDRS parts II+III score over 24 weeks, but the primary comparison and safety findings are not available, preventing assessment of whether the endpoint was met.
LY03009
Developed by Luye Pharma Group
NCT04593511 · Phase 1 · status unknown
This open-label, single-dose pharmacokinetic study compared four different formulations of LY03009 against each other in healthy volunteers, but included no placebo or inactive control arm and no blinding. No results have been posted, and because every arm receives active drug in a different formulation, this design cannot demonstrate a treatment effect once results are available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03003's landscape · LY03009's landscape